An observational study in Cardiogenic Shock, Heart Failure and Shock, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-26.
Sponsored by University Health Network, Toronto · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Shock, Cardiogenic with a site in Canada — 6 open to participants now, 7 under way, none of them phase 3. Shock, Cardiogenic · Canada.
Among the 13 studies in Shock, Cardiogenic with a site in Canada, this one is one of 2 that started in 2021, is one of 7 observational ones, and was the 9th registered.
297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.
Browse Shock, Cardiogenic studies →6 of the 13 studies in Shock, Cardiogenic with a site in Canada are open now. Recruiting first, the newest first:
Laval University · Sites in Canada
Ottawa Heart Institute Research Corporation · Sites in Canada, United States
Ages 18+
STAVROS G DRAKOS · Sites in Canada, United States
Ages 18+
Ottawa Heart Institute Research Corporation · Sites in Canada, United States
Ages 18+
Ottawa Heart Institute Research Corporation · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 200 across 156 observational studies indexed under Shock, Cardiogenic.
Median enrollment 269 across the 6 interventional studies, 100 across the 7 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 13 have an industry lead sponsor. The 10 most frequent:
University Health Network, Toronto is the lead sponsor of 1,441 studies on the registry; 298 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.
University Health Network, Toronto has 1 study filed under Shock, Cardiogenic — fewer than ten, so there is no comparison to draw.
3 of the studies in Shock, Cardiogenic with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05267886Ottawa Heart Institute Research CorporationCAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock | 2026-12 |
| NCT07484828Laval UniversityEvaluation of Acid-base Disorders and Ventilation Settings in Cardiogenic Shock and Post-cardiac Arrest Patients: Comparison With VentilO Algorithm | 2027-06 |
| NCT07756801Ottawa Heart Institute Research CorporationCapital Offload-Shock | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 13 studies in Shock, Cardiogenic with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an investigator-initiated, single-center, single-arm prospective study to compare non-invasive hemodynamic assessment using transthoracic echocardiography (TTE) and lung ultrasound (LUS) and hemodynamic assessment using PAC. Patients who have been hemodynamically assessed using PAC will be invited to participate. Each patient will undergo TTE and LUS immediately after first invasive assessment, and again daily after PAC assessments.
Background
Heart Failure
Approximately 600,000 Canadians are living with heart failure (HF) with 50,000 new patients diagnosed each year. Once diagnosed, the median survival for HF patients is 1.7 years for men and 3.2 years for women. As HF progresses, patients experience a worsening in symptom severity, functional capacity, and quality of life. In addition, acute exacerbations of HF is the most frequent cause of unscheduled hospital admissions. Almost 83% of all HF patients will be hospitalized at least once and 43% hospitalized more than three times. However, the mechanisms of HF decompensation are still unclear.
Most drugs (ACE-I/ARB/beta-blockers/MRA) used for the treatment of HF are prescribed because of their ability to improve symptoms or survival. The target doses of these drugs are generally selected on the basis of reported results from randomized controlled trials rather than changes produced in cardiac monitoring of hemodynamics. Interestingly, hemodynamic monitoring has been reportedly indicated in patients where it is difficult to determine their volume status, in addition to those patients refractory to therapy. The ACC/AHA 2013 guidelines3 define the importance of invasive hemodynamic monitoring in patients with:
Cardiogenic shock
Cardiogenic shock (CS) is a state of profound HF resulting in peripheral organ hypoperfusion, injury and failure. The precipitating events leading to CS are diverse. Patients may experience CS as a slow progression of chronic HF. More frequently however; patients experience CS after an acute cardiac insult such as an acute myocardial infarction, myocarditis or malignant ventricular arrhythmia. It is inevitable that patients who develop CS will die if treatment is not initiated rapidly. In addition, if initial medical therapy fails to maintain adequate cardiac output, initiation of mechanical circulatory support (MCS) represents a life-saving strategy. There has been no established role for the use of invasive hemodynamic measurements in the management of patients with HF. And yet, patients with CS being considered for cardiac transplantation or placement of an MCS device are required to undergo right-heart catheterization using pulmonary artery catheter (PAC), including an assessment of right heart filling pressures, pulmonary artery pressures, left heart filling pressures and cardiac output.
University Health Network (UHN) has the largest and most comprehensive MCS program in Canada. As clinicians working at the Peter Munk Cardiac Centre (PMCC) we are caring for an ever-increasing number of patients with profound refractory cardiogenic shock who require invasive hemodynamic assessment.
Rationale for the study
The majority of patients who present to the CICU require invasive hemodynamic assessment as part of their usual care. To assist in the management of these critically ill patients, the investigators need a complete understanding of the hemodynamic status. Currently, this is usually done invasively by placing a PAC. Alternatively, a non-invasive assessment using transthoracic echocardiography (TTE) can be pursued.
Pulmonary artery Catheter
In early retrospective registries, there was no benefit shown for the use of PAC. However, this had not been studied in patients with CS until recently. In a large retrospective study of CS patients, the use of PAC was associated with improved survival (30% vs 38%). This study provided the basis for the incorporation of PAC into CS treatment algorithms. In addition, the guidelines and scientific statements limited recommendations regarding PAC to use in patients with CS. The hemodynamic data obtained with a PAC can facilitate clinical decision-making and allow customization of a treatment plan through the optimization of medical therapy. However, as with any invasive diagnostic tool, the benefit must be balanced against risks. Complications of PAC include central venous access-related adverse events (\<3.6%), arrhythmias and heart block (0.3% to 3.8%), and pulmonary artery rupture (0.02% to 0.03%).
Transthoracic echocardiography
TTE is a non-invasive ultrasound-based diagnostic tool that has the ability to also evaluate and track both RV and LV hemodynamic status. There is conflicting evidence of the utility of TTE monitoring in reflecting the hemodynamic changes in PAC-derived hemodynamic measurements.
Lung Ultrasound (LUS)
LUS allows for a rapid point-of-care evaluation of a number of conditions, including pulmonary edema, lung consolidation, pleural effusion, and pneumothorax. High intra-rater and inter-rater reproducibility, ease of learning, short exam duration (\<5 min), and the noninvasive nature of this technique makes it an advantageous point-of-care tool. LUS is increasingly used in the acute care setting, and has improved diagnostic accuracy compared with clinical assessment and chest radiography for the identification of a cardiac aetiology in patients presenting to the emergency department with undifferentiated dyspnea. Quantification of B-lines (vertical artefacts that result from an increase in interstitial density) has been shown to be useful for the diagnosis, monitoring, and risk assessment of patients with known or suspected ADHF. Either curvilinear or phased array transducers can be used, typically at an imaging depth of 14-18 cm.
Hypothesis
The investigators hypothesize that non-invasive hemodynamic parameters derived from TTE would be comparable to those obtained invasively by PAC in patient admitted to the CICU. The investigators also hypothesize that there will be a strong correlation between intracardiac pressures and the severity of pulmonary congestion as evaluated by LUS.
The study population will be composed of patients admitted to the Coronary Intensive Care Unit (CICU) requiring hemodynamic assessment using pulmonary artery catheter (PAC) as standard of care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The study population will be composed of patients admitted to the Coronary Intensive Care Unit (CICU) requiring hemodynamic assessment using pulmonary artery catheter (PAC) as standard of care.
Diagnostic Test: Echocardiography and lung ultrasound
All patients will undergo non-invasive echocardiogram and lung ultrasound at times of assessment of hemodynamic parameters as needed by usual clinical management.
Correlation between E/e' ratio and PCWP vs. correlation between lung ultrasound score and PCWP.
To determine whether non-invasive assessment of hemodynamics by echocardiogram are comparable to invasive measurements.
Time frame: Day 1
Correlation between cardiac output measured by echocardiography (using LVOT diameter and VTI) and by PAC (using thermodilution)
To correlate cardiac and pulmonary pressures derived from invasive measurements with lung ultrasound findings.
Time frame: Day 1, Day 2
Correlation between right atrial pressure assessed by echocardiography (using IVC diameter and respiratory variation) and by PAC
To correlate cardiac and pulmonary pressures derived from invasive measurements with lung ultrasound findings.
Time frame: Day 1, Day 2
Correlation between pulmonary pressure assessed by echocardiography (using TR max velocity and estimated RAP) and by PAC
To correlate cardiac and pulmonary pressures derived from invasive measurements with lung ultrasound findings.
Time frame: Day 1, Day 2
Correlation between pulmonary pressure assessed by echocardiography (using PAT) and by PAC
To correlate cardiac and pulmonary pressures derived from invasive measurements with lung ultrasound findings.
Time frame: Day 1, Day 2
Correlation between PVR assessed by echocardiography (using PAT) and by PAC
To correlate cardiac and pulmonary pressures derived from invasive measurements with lung ultrasound findings.
Time frame: Day 1, Day 2
Correlation between right ventricular function assessed by echocardiography (using TAPSE and S') and by PAC (using PAPI and RVSWI)
To correlate cardiac and pulmonary pressures derived from invasive measurements with lung ultrasound findings.
Time frame: Day 1, Day 2
Correlation between E/e' ratio and PCWP vs. correlation between lung ultrasound score and PCWP.
To determine whether non-invasive assessment of hemodynamics by echocardiogram are comparable to invasive measurements.
Time frame: Day 2
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2021 (actual). Primary completion is estimated for Aug 2024, 37 months after the start.
Of 79 non-industry observational studies under Shock, Cardiogenic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 19. This study's planned 37 months is below that.
Counting every sponsor, half of 85 studies reached it within 45 months; a quarter within 24.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Health Network, Toronto →